Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2018 (2018), Article ID 4543065, 8 pages
Research Article

Fibrin Clot Strength in Patients with Diabetes Mellitus Measured by Thrombelastography

Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, IN, USA

Correspondence should be addressed to Rolf P. Kreutz

Received 13 September 2017; Accepted 30 November 2017; Published 4 February 2018

Academic Editor: Giovanni de Gaetano

Copyright © 2018 Benjamin T. Maatman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. Patients with diabetes mellitus (DM) exhibit increased risk of recurrent myocardial infarction. Maximal clot strength measured by thrombelastography (TEG) is a risk factor for recurrent ischemic events. We hypothesized that diabetic subjects exhibit increased fibrin clot strength in platelet-poor plasma and that glycemic control correlates with maximal fibrin clot strength. Methods. We collected plasma samples from subjects with known or suspected coronary artery disease undergoing cardiac catheterization (). We measured kaolin-activated TEG in platelet-poor citrate plasma. Time to fibrin formation (R), clot formation time (K), and maximal fibrin clot strength (MA) were recorded. Results. Plasma fibrin MA was increased among subjects with DM () as compared to non-DM () (37.0 ± 8 versus 34.1 ± 8 mm; ). Hemoglobin A1c (HbA1c) (; ) and fibrinogen (; ) correlated with fibrin MA. In multivariable regression analysis, DM remained significantly associated with plasma MA after adjustment for fibrinogen level (). Conclusions. Subjects with diabetes mellitus exhibit increased maximal fibrin clot strength measured by TEG in platelet-poor plasma.